Janux Therapeutics (JANX) Cash from Operations (2020 - 2026)
Janux Therapeutics (JANX) reported Cash from Operations of 12337000.0 for Q1 2026, up 27.53% year-over-year from 9673671.78 in Q1 2025, and up 56.78% quarter-over-quarter from 28542000.0 in Q4 2025.
Janux Therapeutics (JANX) Cash from Operations (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Cash from Operations data on file, last reported at 12337000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 12337000.0, up 27.53% year-over-year; the trailing twelve-month figure through Mar 2026 was 77548000.0 (down 68.58% YoY), and the FY2025 annual result was 82235000.0, down 87.69% from the prior year.
- Cash from Operations rose to 12337000.0 in Q1 2026 per JANX's latest filing, from 28542000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2231000.0 in Q3 2024 and troughed at 28542000.0 in Q4 2025.
- A 5-year average of 13640176.47 and a median of 12856000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 80.95% in 2024, then plunged 476.24% in 2025.
- A 5-year view of Cash from Operations shows it stood at 11913000.0 in 2022, then grew by 16.89% to 9901000.0 in 2023, then tumbled by 68.92% to 16725000.0 in 2024, then tumbled by 70.65% to 28542000.0 in 2025, then surged by 56.78% to 12337000.0 in 2026.
- Business Quant data shows JANX's Cash from Operations at 12337000.0 in Q1 2026, 28542000.0 in Q4 2025, and 12856000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -12.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.34 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Dec 31, 2025 | -28.54 Mn |
| Dec 31, 2025 | -28.54 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Jun 30, 2025 | -23.81 Mn |
| Jun 30, 2025 | -23.81 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -16.73 Mn |
| Dec 31, 2024 | -16.73 Mn |
| Sep 30, 2024 | -2.23 Mn |
| Sep 30, 2024 | -2.23 Mn |
| Jun 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -10.02 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Dec 31, 2023 | -9.90 Mn |
| Dec 31, 2023 | -9.90 Mn |